270 related articles for article (PubMed ID: 28974543)
1. Spleen-derived IFN-γ induces generation of PD-L1
Langereis JD; Pickkers P; de Kleijn S; Gerretsen J; de Jonge MI; Kox M
J Leukoc Biol; 2017 Dec; 102(6):1401-1409. PubMed ID: 28974543
[TBL] [Abstract][Full Text] [Related]
2. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
[TBL] [Abstract][Full Text] [Related]
3. Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1.
Patera AC; Drewry AM; Chang K; Beiter ER; Osborne D; Hotchkiss RS
J Leukoc Biol; 2016 Dec; 100(6):1239-1254. PubMed ID: 27671246
[TBL] [Abstract][Full Text] [Related]
4. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
[TBL] [Abstract][Full Text] [Related]
5. IFN-γ-stimulated neutrophils suppress lymphocyte proliferation through expression of PD-L1.
de Kleijn S; Langereis JD; Leentjens J; Kox M; Netea MG; Koenderman L; Ferwerda G; Pickkers P; Hermans PW
PLoS One; 2013; 8(8):e72249. PubMed ID: 24015224
[TBL] [Abstract][Full Text] [Related]
6. Farnesyltransferase inhibitor FTI-277 inhibits PD-L1 expression on septic spleen lymphocytes and promotes spleen lymphocyte activation.
Li W; Tu J; Liu X; Yang W
Clin Exp Immunol; 2017 Oct; 190(1):8-18. PubMed ID: 28556912
[TBL] [Abstract][Full Text] [Related]
7. Immune regulation of canine tumour and macrophage PD-L1 expression.
Hartley G; Faulhaber E; Caldwell A; Coy J; Kurihara J; Guth A; Regan D; Dow S
Vet Comp Oncol; 2017 Jun; 15(2):534-549. PubMed ID: 26842912
[TBL] [Abstract][Full Text] [Related]
8. Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells.
Yuan LW; Jiang XM; Xu YL; Huang MY; Chen YC; Yu WB; Su MX; Ye ZH; Chen X; Wang Y; Lu JJ
Phytomedicine; 2021 Jan; 80():153394. PubMed ID: 33130472
[TBL] [Abstract][Full Text] [Related]
9. Polymorphonuclear Myeloid-Derived Cells That Contribute to the Immune Paralysis Are Generated in the Early Phase of Sepsis via PD-1/PD-L1 Pathway.
Ao X; Yang Y; Okiji T; Azuma M; Nagai S
Infect Immun; 2021 May; 89(6):. PubMed ID: 33753411
[TBL] [Abstract][Full Text] [Related]
10. Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment.
Xiong H; Mittman S; Rodriguez R; Moskalenko M; Pacheco-Sanchez P; Yang Y; Nickles D; Cubas R
Cancer Res; 2019 Apr; 79(7):1493-1506. PubMed ID: 30679180
[TBL] [Abstract][Full Text] [Related]
11. Endogenous programmed death ligand-1 restrains the development and onset of Sjӧgren's syndrome in non-obese diabetic mice.
Zhou J; Jin JO; Kawai T; Yu Q
Sci Rep; 2016 Dec; 6():39105. PubMed ID: 27966604
[TBL] [Abstract][Full Text] [Related]
12. Glial cells suppress postencephalitic CD8+ T lymphocytes through PD-L1.
Schachtele SJ; Hu S; Sheng WS; Mutnal MB; Lokensgard JR
Glia; 2014 Oct; 62(10):1582-94. PubMed ID: 24890099
[TBL] [Abstract][Full Text] [Related]
13. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.
Abiko K; Matsumura N; Hamanishi J; Horikawa N; Murakami R; Yamaguchi K; Yoshioka Y; Baba T; Konishi I; Mandai M
Br J Cancer; 2015 Apr; 112(9):1501-9. PubMed ID: 25867264
[TBL] [Abstract][Full Text] [Related]
14. Neutrophils Which Migrate to Lymph Nodes Modulate CD4
Castell SD; Harman MF; Morón G; Maletto BA; Pistoresi-Palencia MC
Front Immunol; 2019; 10():105. PubMed ID: 30761151
[TBL] [Abstract][Full Text] [Related]
15. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.
Gao Y; Yang J; Cai Y; Fu S; Zhang N; Fu X; Li L
Int J Cancer; 2018 Aug; 143(4):931-943. PubMed ID: 29516506
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-155 induction via TNF-α and IFN-γ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells.
Yee D; Shah KM; Coles MC; Sharp TV; Lagos D
J Biol Chem; 2017 Dec; 292(50):20683-20693. PubMed ID: 29066622
[TBL] [Abstract][Full Text] [Related]
17. Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway.
Chen J; Feng Y; Lu L; Wang H; Dai L; Li Y; Zhang P
Immunobiology; 2012 Apr; 217(4):385-93. PubMed ID: 22204817
[TBL] [Abstract][Full Text] [Related]
18. Nasopharyngeal cancer cell-derived exosomal PD-L1 inhibits CD8+ T-cell activity and promotes immune escape.
Yang J; Chen J; Liang H; Yu Y
Cancer Sci; 2022 Sep; 113(9):3044-3054. PubMed ID: 35598173
[TBL] [Abstract][Full Text] [Related]
19. PD-L1/B7-H1 Inhibits Viral Clearance by Macrophages in HSV-1-Infected Corneas.
Jeon S; Rowe AM; Carroll KL; Harvey SAK; Hendricks RL
J Immunol; 2018 Jun; 200(11):3711-3719. PubMed ID: 29669784
[TBL] [Abstract][Full Text] [Related]
20. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
